Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors

scientific article published on 01 January 1995

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/BF00686555
P698PubMed publication ID7805184

P2093author name stringJ P Guastalla
Y Merrouche
G Catimel
M Clavel
A Dumortier
M Foy
M K Alakl
N Le Bail
R Coquard
P2860cites workClinical trials in cancer chemotherapyQ39635134
Antitumor activity and mechanism of action of the marine compound girodazoleQ44717791
P433issue3
P304page(s)246-248
P577publication date1995-01-01
P1433published inCancer Chemotherapy and PharmacologyQ326137
P1476titlePhase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors
P478volume35

Reverse relations

cites work (P2860)
Q37873742Biosynthesis, asymmetric synthesis, and pharmacology, including cellular targets, of the pyrrole-2-aminoimidazole marine alkaloids
Q33519074Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.
Q26753021Marine Natural Products from New Caledonia--A Review
Q73668726Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
Q35211600Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis

Search more.